SGS’ Glasgow biosafety facility doubles in size

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Tuomas Lehitnen)
(Image: Getty/Tuomas Lehitnen)

Related tags: SGS, Scotland, Biologics, Vaccines, cell and gene therapy, Cell therapy, Gene therapy, Monoclonal antibodies, Monoclonal antibody, Testing

SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.

The expansion of SGS’ UK site doubled the total floor space of the facility from 1,200 square-meters to 2,400 square-meters providing the inspection, verification, testing, and certification company with space for additional capabilities.

The facility is currently awaiting operational validation but, once approved, will provide services for testing cell banks and routine bulk harvest for vaccines, gene and cell therapies, monoclonal antibodies (mAbs) and other recombinant protein-based biological medicines.

The company supports biological medicines in early development, through clinical development, and commercial products.

Expansion of the biosafety site came after a ₤7m ($8.86m) investment from the company and a ₤1.7m R&D grant from the Scottish government.  

The company will also increase its capacity for existing biosafety services and enhanced real-time polymerase chain reaction (PCR) platforms. A spokesperson for SGS told us that the expanded facilty will triple the capacity of such services.

Archie Lovatt, scientific director at SGS, said in a statement, “Our investment ensures we will remain at the forefront of this growth by delivering the highly specialized testing expertise necessary to establish and ensure the safety of novel human therapies and vaccines.”

The testing company has 18 laboratories worldwide, offering its contract analytical and bioanalytical services in North America, Europe, and Asia to pharmaceutical and biotech companies.

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars